Niraparib Archives - Medical Conferences

No OS benefit of niraparib maintenance in high-risk ovarian cancer

Presented By

Dr Antonio González-Martin, Clínica Universidad de Navarra, Spain

Trial

Phase 3, PRIMA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:15

Addition of atezolizumab to chemotherapy and maintenance PARP inhibitor has no benefit in ovarian cancer

Presented By

Prof. Antonio Gonzalez Martin, Cancer Centre Clinica Universidad de Navarre, Spain

Trial

Phase 3, ANITA

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:43

First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC

Presented By

Dr Kim Chi, University of British Columbia, Canada

Trial

Phase 3, MAGNITUDE

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:25

Maintenance niraparib fails to improve PFS in advanced urothelial cancer

Presented By

Dr Francesca Vignani, Ordine Mauriziano Hospital, Italy

Trial

Phase 2, Meet-URO12

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

PARP inhibitor rechallenge improves PFS in ovarian cancer

Presented By

Dr Eric Pujade-Lauraine, Université Paris Descartes, France

Trial

Phase 3, OReO/ENGOT Ov-38

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:24

Treatment of recurrent ovarian cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:35

PFS benefit with niraparib as first-line maintenance in ovarian cancer

Principal Investigator

Prof. Antonio González Martín, Clinica Universidad de Navarra, Spain

Trial

Phase 3, PRIMA/ENGOT-OV26/GOG-3012

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 14:26